Chromenopyrazole-based High Affinity, Selective Fluorescent Ligands for Cannabinoid Type 2 Receptor

被引:31
作者
Singh, Sameek [1 ]
Oyagawa, Caitlin R. M. [2 ,3 ]
Macdonald, Christa [2 ,3 ]
Grimsey, Natasha L. [2 ,3 ]
Glass, Michelle [2 ,3 ,4 ]
Vernall, Andrea J. [1 ]
机构
[1] Univ Otago, Sch Pharm, Dunedin, New Zealand
[2] Univ Auckland, Sch Med Sci, Dept Pharmacol & Clin Pharmacol, Fac Med & Hlth Sci, Auckland, New Zealand
[3] Univ Auckland, Sch Med Sci, Ctr Brain Res, Fac Med & Hlth Sci, Auckland, New Zealand
[4] Univ Otago, Dept Pharmacol & Toxicol, Dunedin 9016, New Zealand
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2019年 / 10卷 / 02期
关键词
GPCR; cannabinoid type 2 receptor; fluorescent ligand; chemical tool; CB2; RECEPTOR; ENDOCANNABINOID SYSTEM; SCAFFOLD; AGONISTS; PROBES; TOOLS;
D O I
10.1021/acsmedchemlett.8b00597
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cannabinoid type 2 receptor (CB2R) is an attractive target for the treatment of pain and inflammatory disorders. Availability of a selective CB2R fluorescent ligand to study CB2R expression and localization in healthy and disease conditions would greatly contribute to improving our understanding of this receptor. Herein, we report a series of chromenopyrazole-based CB2R fluorescent ligands. The highest affinity fluorescent ligand was Cy5-containing 24 (hCB(2)R pK(i), = 7.38 +/- 0.05), which had 131-fold selectivity over CB1R. In a cAMP BRET assay, 24 behaved as a potent CB2R. inverse agonist. Widefield imaging experiments showed that 24 binds to CB2R in live cells with good selectivity and low levels of nonspecific fluorescence. The high affinity, selectivity, and suitable imaging properties of fluorescent ligand 24 make it a valuable tool for studying CB2R.
引用
收藏
页码:209 / 214
页数:11
相关论文
共 50 条
  • [41] Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor
    Han, Shuang
    Zhang, Fei-Fei
    Qian, Hai-Yan
    Chen, Li-Li
    Pu, Jian-Bin
    Xie, Xin
    Chen, Jian-Zhong
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (15) : 5751 - 5769
  • [42] Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands
    Bhattacharjee, Himanshu
    Gurley, Steven N.
    Moore, Bob M., II
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (06) : 1691 - 1693
  • [43] Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases
    Carbone, Federico
    Mach, Francois
    Vuilleumier, Nicolas
    Montecucco, Fabrizio
    [J]. CURRENT MEDICINAL CHEMISTRY, 2014, 21 (35) : 4046 - 4058
  • [44] Synthesis and Biological Evaluation of Thiophene-Based Cannabinoid Receptor Type 2 Radiotracers for PET Imaging
    Haider, Ahmed
    Herde, Adrienne Mueller
    Slavik, Roger
    Weber, Markus
    Mugnaini, Claudia
    Ligresti, Alessia
    Schibli, Roger
    Mu, Linjing
    Ametamey, Simon Mensah
    [J]. FRONTIERS IN NEUROSCIENCE, 2016, 10
  • [45] Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment
    Cooper, Anna G.
    MacDonald, Christa
    Glass, Michelle
    Hook, Sarah
    Tyndall, Joel D. A.
    Vernall, Andrea J.
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 145 : 770 - 789
  • [46] Resorcinol-sn-Glycerol Derivatives: Novel 2-Arachidonoylglycerol Mimetics Endowed with High Affinity and Selectivity for Cannabinoid Type 1 Receptor
    Brizzi, Antonella
    Cascio, Maria Grazia
    Frosini, Maria
    Ligresti, Alessia
    Aiello, Francesca
    Biotti, Irene
    Brizzi, Vittorio
    Pertwee, Roger Guy
    Corelli, Federico
    Di Marzo, Vincenzo
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (24) : 8278 - 8288
  • [47] Development of Oxygen-Bridged Pyrazole-Based Structures as Cannabinoid Receptor 1 Ligands
    Murineddu, Gabriele
    Asproni, Battistina
    Corona, Paola
    Piras, Sandra
    Lazzari, Paolo
    Ruiu, Stefania
    Legnani, Laura
    Toma, Lucio
    Pinna, Gerard A.
    [J]. MOLECULES, 2019, 24 (09):
  • [48] Clinical Importance of Cannabinoid Type 1 Receptor (CB1R) and Cannabinoid Type 2 Receptor (CB2R) Expression in Renal Cell Carcinoma
    Deligiannis, Dimitrios
    Anastasiou, Ioannis
    Mitropoulos, Dionysios
    Mitsos, Panagiotis
    Theocharis, Stamatios
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (02)
  • [49] Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy
    Zoja, Carlamaria
    Locatelli, Monica
    Corna, Daniela
    Villa, Sebastian
    Rottoli, Daniela
    Nava, Valeria
    Verde, Roberta
    Piscitelli, Fabiana
    Di Marzo, Vincenzo
    Fingerle, Juergen
    Adam, Jean-Michel
    Rothenhaeusler, Benno
    Ottaviani, Giorgio
    Benardeau, Agnes
    Abbate, Mauro
    Rernuzzi, Giuseppe
    Benigni, Ariela
    [J]. NEPHRON, 2016, 132 (01) : 59 - 69
  • [50] New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies
    Urbani, P
    Cavallo, P
    Cascio, MG
    Buonerba, M
    De Martino, G
    Di Marzo, V
    Saturnino, C
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (01) : 138 - 141